EP 0632808 A1 19950111 - ANTIVIRAL PEPTIDES.
Title (en)
ANTIVIRAL PEPTIDES.
Title (de)
ANTIVIRALE PEPTIDE.
Title (fr)
PEPTIDES ANTIVIRAUX.
Publication
Application
Priority
- EP 9300597 W 19930313
- GB 9206462 A 19920325
- GB 9301638 A 19930127
Abstract (en)
[origin: WO9319059A1] Compounds of formula (I) and pharmaceutically acceptable salts thereof and bioprecursors therefore wherein R<1> is C1-C6 alkyl, C3-C8 cycloalkyl, aryl, heterocyclyl or CONR<9>R<10>; R<2> is C1-C6 alkyl, C3-C8 cycloalkyl(C1-C4)alkyl, aryl(C1-C4)alkyl or heterocyclyl(C1-C4)alkyl; R<3> is C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl(C1-C4)alkyl, aryl(C1-C4)alkyl, aryl(C2-C4)-alkenyl, heterocyclyl(C1-C4)alkyl or heterocyclyl(C2-C4)-alkenyl; R<4> is C1-C6 alkyl, C3-C8 cycloalkyl, aryl or heterocyclyl; each of R<5>, R<6>, R<7> and R<8> is independently H, C1-C6 alkyl or C3-C8 cycloalkyl; or R<5> and R<6>, or R<7> and R<8> may be joined together to form a 3 to 8 membered carbocyclic ring; X is a 4-10 membered mono or bicyclic heterocyclic group containing carbon ring atoms and one ring nitrogen atom through which the group is attached to the adjacent carbonyl group; the group may be saturated or partially unsaturated and, in addition to the -(CR<7>R<8>)m-Het substituent, it may be substituted by up to 4 further substituents independently chosen from F, C1-C6 alkyl, C3-C8 cycloalkyl, OR<11> or NR<9>R<10>; Het is an imidazolyl or triazolyl group either of which may optionally be substituted by C1-C6 alkyl, C3-C7 cycloalkyl, NR<9>R<10> or CONR<9>R<10>, each of R<9> and R<10> is independently H, C1-C6 alkyl or C3-C8 cycloalkyl, or R<9> and R<10> may be joined together to form, with the nitrogen to which they are attached, a 4 to 8 membered nitrogen-containing heterocyclic group, R<11> is H, C1-C6 alkyl or C3-C8 cycloalkyl; n and m are each independently 0, 1 or 2; wherein any alkyl or cycloalkyl group included in the aforementioned definitions may optionally be fully or partially substituted by fluorine; are inhibitors of retroviral proteases of utility in the treatment and prophylaxis of human retroviral infections.
IPC 1-7
IPC 8 full level
A61K 31/415 (2006.01); A61K 31/4427 (2006.01); A61K 31/445 (2006.01); A61P 31/12 (2006.01); A61P 37/04 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 405/14 (2006.01)
CPC (source: EP KR)
A61P 31/12 (2017.12 - EP); A61P 37/04 (2017.12 - EP); C07D 401/04 (2013.01 - EP KR); C07D 401/14 (2013.01 - EP); C07D 403/04 (2013.01 - EP KR); C07D 405/14 (2013.01 - EP)
Citation (search report)
See references of WO 9319059A1
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9319059 A1 19930930; AU 3748393 A 19931021; BR 9306138 A 19980623; CA 2131154 A1 19930930; CZ 229594 A3 19950412; EP 0632808 A1 19950111; FI 944428 A0 19940923; FI 944428 A 19940923; HU 9402744 D0 19941228; JP H07501556 A 19950216; KR 950700901 A 19950220; NO 943540 D0 19940923; NO 943540 L 19941121; RU 94041225 A 19960720; SK 114094 A3 19950412
DOCDB simple family (application)
EP 9300597 W 19930313; AU 3748393 A 19930313; BR 9306138 A 19930313; CA 2131154 A 19930313; CZ 229594 A 19930313; EP 93906535 A 19930313; FI 944428 A 19940923; HU 9402744 A 19930313; JP 51623693 A 19930313; KR 19940703314 A 19940924; NO 943540 A 19940923; RU 94041225 A 19940923; SK 114094 A 19930313